Abingdon Health PLC Judicial Review -- judgement expected at 3pm (1740C)

TIDMABDX

RNS Number : 1740C

Abingdon Health PLC

07 October 2022

Abingdon Health plc

("Abingdon Health" or "the Company")

Judicial Review - judgement expected at 3pm

York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, notes that the judgement in relation to the Judicial Review proceedings initiated by the Good Law Project Limited ("GLP") against the Department of Health and Social Care ("DHSC") is now expected to be handed down at 3pm today. Abingdon Health is an interested party in the case.

Details are provided in section 17.4 of this link:

https://www.gov.uk/government/publications/business-and-property-courts-rolls-building-cause-list/business-and-property-courts-of-england-and-wales-cause-list#technology-and-construction-court-kings-bench-division

A further announcement will be made once the outcome of the Judicial Review is known.

Enquiries

 
 Abingdon Health plc                                       www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                        Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Chris Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                            Tel: [phone] 
  Nominated Adviser) 
 Peter Steel, Alex Bond (Corporate Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited                     Tel: [phone] or [e-mail] 
 Paul McManus / Phillip Marriage                      Mob: [phone] 
  Alice Woodings                                                                     984 082 
                                                                         [phone] 
 
 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality lateral flow rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBKOBNCBDKNKK

(END) Dow Jones Newswires

October 07, 2022 05:35 ET (09:35 GMT)